Sugi Predict

Sugi Predict / Compounds / SCHEMBL24623

SCHEMBL24623

SCHEMBL24623

CC(C)(C)C(CBr)OC(N)=O

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.36
▸ TSHR P16473 3/20 0.36
▸ CHRM2 P08172 1/20 0.36
▸ CHRM4 P08173 1/20 0.36
▸ CHRM5 P08912 1/20 0.36
▸ CHRM1 P11229 1/20 0.36
▸ CHRM3 P20309 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ MAPT P10636 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ ALOX15 P16050 1/20 0.31
▸ CYP3A4 P08684 1/20 0.30
▸ NFKB1 P19838 1/20 0.30
▸ ADRA1A P35348 1/20 0.30
▸ RAB9A P51151 1/20 0.30
▸ TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1148559 0.83 LMNA (0.34) LMNATSHRCHRM2CHRM4CHRM5
SCHEMBL2348467 0.80 LMNA (0.32) LMNATSHRCHRM2CHRM4CHRM5
SCHEMBL28415266 0.80 LMNA (0.38) LMNATSHRCHRM2CHRM4CHRM5
SCHEMBL1829129 0.80 LMNA (0.38) LMNATSHRCHRM2CHRM4CHRM5
SCHEMBL445644 0.80 LMNA (0.38) LMNATSHRCHRM2CHRM4CHRM5
SCHEMBL28418994 0.80 LMNA (0.38) LMNATSHRCHRM2CHRM4CHRM5
SCHEMBL20416250 0.80 LMNA (0.41) LMNATSHRCHRM2CHRM4CHRM5
SCHEMBL4966129 0.78 LMNA (0.36) LMNATSHRCHRM2CHRM4CHRM5
SCHEMBL2474842 0.78 LMNA (0.36) LMNATSHRCHRM2CHRM4CHRM5
SCHEMBL3902485 0.78 LMNA (0.39) LMNATSHRCHRM2CHRM4CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115579-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2025-04-10 — — US disclosed
EP-4433040-A2 ACYCLIC THIOL PRODRUGS Lilac Therapeutics, Inc. (US) 2024-09-25 — — EP disclosed
US-20240270767-A1 Acyclic Thiol Prodrugs HARP BIO INC. 2024-08-15 — — US disclosed
US-11981694-B2 Acyclic thiol prodrugs Lilac Therapeutics, Inc. (US) 2024-05-14 — — US disclosed
US-20230212200-A1 Acyclic Thiol Prodrugs HARP BIO INC. 2023-07-06 — — US disclosed
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2023-07-06 — — US disclosed
WO-2023129576-A2 ACYCLIC THIOL PRODRUGS Lilac Therapeutics, Inc. (US) 2023-07-06 — — WO disclosed
EP-4159718-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS Daegu-Gyeongbuk Medical Innovation Foundation (KR) 2023-04-05 — — EP disclosed
CN-114437062-A Compound capable of being used as sodium channel regulator and application thereof 成都海博为药业有限公司 2022-05-06 — — CN disclosed
CN-108440370-B Inhibitors of viral replication 鲁汶天主教大学 2021-07-30 — — CN disclosed
EP-2931282-A1 PYRIMIDO [4,5-B]QUINOLINE-4,5 (3H,10H)-DIONES AS NONSENSE MUTATION SUPPRESSORS Novartis AG (CH) 2015-10-21 — — EP disclosed
US-20150266875-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-09-24 — — US disclosed
WO-2014091446-A1 PYRIMIDO [4,5-B]QUINOLINE-4,5 (3H,10H)-DIONES AS NONSENSE MUTATION SUPPRESSORS NOVARTIS AG (CH) 2014-06-19 — — WO disclosed
WO-2011161537-A2 3,4-DIHYDROPYRROLO[1,2-A]PYRAZINE-2,8(1H)-DICARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2011-12-29 — — WO disclosed
EP-0976722-B1 BENZAMIDINE DERIVATIVES AJINOMOTO KK (JP) 2009-03-11 — — EP disclosed
EP-1236712-B1 AMIDINOPHENYLPYRUVIC ACID DERIVATIVE AJINOMOTO KK (JP) 2008-08-06 — — EP disclosed
US-6710056-B2 PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVE AN EXCELLENT ANTAGONISTIC EFFECT AGAINST ACTIVATED BLOOD COAGULATION FACTOR VII. AJINOMOTO CO., INC. (JP) 2004-03-23 — — US disclosed
US-20030109547-A1 Amidinophenylpyruvic acid derivatives AJINOMOTO CO. INC (JP) 2003-06-12 — — US disclosed
EP-1236712-A1 AMIDINOPHENYLPYRUVIC ACID DERIVATIVE Ajinomoto Co., Inc. (JP) 2002-09-04 — — EP disclosed
EP-0976722-A1 BENZAMIDINE DERIVATIVES Ajinomoto Co., Inc. (JP) 2000-02-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250115579-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS CGAS, GLS2, GLS LMNA 1681/4885TSHR 2355/4885CHRM2 611/4885
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS SLC6A2, SLC6A3, SLC6A4 LMNA 3772/4885TSHR 2366/4885CHRM2 649/4885
US-20240270767-A1 Acyclic Thiol Prodrugs CTH, GLS2, SLC7A11 LMNA 4318/4885TSHR 1309/4885CHRM2 1635/4885
US-20030109547-A1 Amidinophenylpyruvic acid derivatives HABP2, F2, F7 LMNA 3957/4885TSHR 2157/4885CHRM2 3804/4885
US-20150266875-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 LMNA 2078/4885TSHR 1652/4885CHRM2 4803/4885
US-20230212200-A1 Acyclic Thiol Prodrugs CTH, GLS2, SLC7A11 LMNA 4318/4885TSHR 1309/4885CHRM2 1635/4885
US-11981694-B2 Acyclic thiol prodrugs CTH, GLS2, SLC7A11 LMNA 4318/4885TSHR 1309/4885CHRM2 1635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.